The insider sales are small relative to market cap and coincide with equity grants, making them likely routine tax-covering transactions. Monitor for any material news (pipeline updates, partnership announcements) that could explain the timing, but this cluster alone does not warrant a bearish view. The strong historical performance of insider buys at this company is not applicable here, as this is a sell cluster.
Price Chart
Executive Summary
Four Artiva Biotherapeutics insiders, including the CEO, COO, CTO, and CMO, sold a total of $477K in open-market shares over a one-week window. The CEO's sale of $256K represents the largest portion. These sales occurred alongside a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven to cover tax obligations from vesting awards, rather than a bearish signal on the company's prospects. The dollar amount is modest relative to the $500M market cap (0.1%), and the historical track record of bullish insider signals at this company has been strong, but this cluster is a sell, not a buy.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 23,400 shares for $256K on 2026-09-08.
- COO Jennifer Bush sold 8,400 shares for $94K on 2026-09-03.
- CTO Christopher Horan sold 10,400 shares for $116K on 2026-09-03.
- CMO Subhashis Banerjee sold 1,100 shares for $12K on 2026-09-03.
- Total insider sales of $477K represent ~0.1% of the $500M market cap.
- All four insiders also received non-cash equity grants (code A) on 2026-09-09 and 2026-09-10, suggesting sales may be tax-related.
Financial Impact
Insider sales of $477K, or ~0.1% of market cap, are trivial in size.
Risk Factors
- Insider sales could signal a lack of confidence if they accelerate or increase in size.
- The company is a pre-revenue biotech; any negative pipeline data would be highly impactful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789448558310 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access